zoledronic acid has been researched along with imatinib mesylate in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (83.33) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cohen, MH; Dagher, R; Griebel, DJ; Ibrahim, A; Martin, A; Pazdur, R; Scher, NS; Sokol, GH; Williams, GA | 1 |
| Enjo, F; Kimura, S; Kobayashi, Y; Kuroda, J; Maekawa, T; Ottmann, OG; Segawa, H; Tokuda, H; Ueda, T; Urasaki, Y; Yoshikawa, T | 1 |
| Kimura, S; Kuroda, J; Maekawa, T; Nogawa, M; Ottmann, OG; Sato, K; Segawa, H; Yuasa, T | 1 |
| Beer, TM; Garzotto, M; Tiffany, NM; Wersinger, EM | 1 |
| Altundag, K; Altundag, O; Gunduz, M; Morandi, P | 1 |
| Salmons, B | 1 |
| Fan, D; Fidler, IJ; He, J; Kim, SJ; Langley, RR; Mathew, P; Uehara, H; Yazici, S | 1 |
| Ashihara, E; Fujiyama, Y; Kamitsuji, Y; Kawata, E; Kimura, S; Kuroda, J; Maekawa, T; Ottmann, OG; Sato, K; Segawa, H; Yokota, A; Yuasa, T | 1 |
| Barnes, DJ; Chuah, C; Corbin, A; Deininger, MW; Druker, BJ; Kwok, M; Melo, JV | 1 |
| Andreasson, C; Apperley, JF; Chuah, C; Goldman, JM; Kaeda, J; Marin, D; Pavlu, J | 1 |
| Campbell-Baird, C; Costa, L; Demers, L; Harvey, H; Kim, C; Lipton, A | 1 |
| Caccamo, N; D'Asaro, M; Di Liberto, D; Di Raimondo, F; Dieli, F; Fourniè, JJ; Guggino, G; La Mendola, C; Meraviglia, S; Messina, A; Orlando, V; Salerno, A; Spina, M; Stassi, G; Todaro, M; Vigneri, P | 1 |
3 trial(s) available for zoledronic acid and imatinib mesylate
| Article | Year |
|---|---|
Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer.
Topics: Aged; Antineoplastic Agents; Benzamides; Bone Diseases; Bone Neoplasms; Bone Resorption; Diphosphonates; Disease Progression; Drug Therapy, Combination; Humans; Imatinib Mesylate; Imidazoles; Male; Middle Aged; Pain; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrimidines; Treatment Failure; Zoledronic Acid | 2004 |
Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission.
Topics: Adult; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Cytogenetic Analysis; Diphosphonates; Drug Administration Schedule; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; ras Proteins; Remission Induction; Signal Transduction; Zoledronic Acid | 2007 |
Phase I trial of zoledronic acid + imatinib mesylate (Gleevec) in patients with bone metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imatinib Mesylate; Imidazoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Staging; Piperazines; Prognosis; Prostatic Neoplasms; Pyrimidines; Sarcoma; Survival Rate; Treatment Outcome; Zoledronic Acid | 2010 |
9 other study(ies) available for zoledronic acid and imatinib mesylate
| Article | Year |
|---|---|
U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bone Neoplasms; Cystitis; Diphosphonates; Drug Approval; Gastrointestinal Neoplasms; Hematuria; Hemorrhage; Humans; Ifosfamide; Imatinib Mesylate; Imidazoles; Mesna; Multiple Myeloma; Orphan Drug Production; Piperazines; Protective Agents; Pyrimidines; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration; Zoledronic Acid | 2002 |
The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate.
Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Cell Division; Diphosphonates; Drug Synergism; Hematopoietic Stem Cells; HL-60 Cells; Humans; Imatinib Mesylate; Imidazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred NOD; Mice, SCID; Monomeric GTP-Binding Proteins; Pamidronate; Piperazines; Protein Prenylation; Pyrimidines; Zoledronic Acid | 2003 |
Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines.
Topics: Antineoplastic Agents; Benzamides; Cell Death; Cell Division; Cell Line, Tumor; Cytarabine; Daunorubicin; Diphosphonates; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Hydroxyurea; Imatinib Mesylate; Imidazoles; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Piperazines; Pyrimidines; Vincristine; Zoledronic Acid | 2004 |
Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Diphosphonates; Humans; Imatinib Mesylate; Imidazoles; Male; Neoplasm Proteins; Palliative Care; Piperazines; Prostatic Neoplasms; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Treatment Failure; Zoledronic Acid | 2005 |
Phacilitate Cell and Gene Therapy Forum 2005. Cell and gene therapy: a corporate perspective. 24-26 January 2005, Washington, DC, USA.
Topics: Antineoplastic Agents; Benzamides; Camptothecin; Cell- and Tissue-Based Therapy; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diphosphonates; Entrepreneurship; Genetic Therapy; Humans; Imatinib Mesylate; Imidazoles; Molecular Structure; Phthalazines; Piperazines; Pyridines; Pyrimidines; Zoledronic Acid | 2005 |
Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Bone and Bones; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imatinib Mesylate; Imidazoles; Immunohistochemistry; Male; Mice; Mice, Nude; Osteoclasts; Paclitaxel; Piperazines; Prostatic Neoplasms; Pyrimidines; Zoledronic Acid | 2005 |
Zoledronate synergises with imatinib mesylate to inhibit Ph primary leukaemic cell growth.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Diphosphonates; Drug Synergism; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, SCID; Models, Animal; Neoplasm Transplantation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Tumor Cells, Cultured; Zoledronic Acid | 2005 |
Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle; Cell Proliferation; Diphosphonates; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Genes, abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Tumor Cells, Cultured; Zoledronic Acid | 2005 |
V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells.
Topics: Adult; Animals; Benzamides; Cells, Cultured; Coculture Techniques; Diphosphonates; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Imidazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Activation; Mice; Mice, SCID; Piperazines; Pyrimidines; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes, Cytotoxic; Zoledronic Acid | 2010 |